Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.

N. Nathalie Bouwer; T. G. Steenbruggen; H. N. Rier; J. J. E. M. Kitzen; K. J. Beelen; A. J. Ten Tije; P. C. De Jong; J. C. Drooger; C. Holterhues; J. Van Rosmalen; M. J. M. Kofflard; E. Boersma; G. S. Sonke; M-D Levin; A. Jager

Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.

N. Nathalie Bouwer, T. G. Steenbruggen, H. N. Rier, J. J. E. M. Kitzen, K. J. Beelen, A. J. Ten Tije, P. C. De Jong, J. C. Drooger, C. Holterhues, J. Van Rosmalen, M. J. M. Kofflard, E. Boersma, G. S. Sonke, M-D Levin, A. Jager

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

Original language	English
Pages (from-to)	289-290
Number of pages	2
Journal	European Journal of Heart Failure
Volume	21
Publication status	Published - May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Bouwer, N. N., Steenbruggen, T. G., Rier, H. N., Kitzen, J. J. E. M., Beelen, K. J., Ten Tije, A. J., De Jong, P. C., Drooger, J. C., Holterhues, C., Van Rosmalen, J., Kofflard, M. J. M., Boersma, E., Sonke, G. S., Levin, M-D., & Jager, A. (2019). Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors. European Journal of Heart Failure, 21, 289-290.

@article{6a02f31f54f1446d9b098928dd33849c,

title = "Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.",

author = "Bouwer, {N. Nathalie} and Steenbruggen, {T. G.} and Rier, {H. N.} and Kitzen, {J. J. E. M.} and Beelen, {K. J.} and {Ten Tije}, {A. J.} and {De Jong}, {P. C.} and Drooger, {J. C.} and C. Holterhues and {Van Rosmalen}, J. and Kofflard, {M. J. M.} and E. Boersma and Sonke, {G. S.} and M-D Levin and A. Jager",

year = "2019",

month = may,

language = "English",

volume = "21",

pages = "289--290",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley-Blackwell",

}

Bouwer, NN, Steenbruggen, TG, Rier, HN, Kitzen, JJEM, Beelen, KJ, Ten Tije, AJ, De Jong, PC, Drooger, JC, Holterhues, C, Van Rosmalen, J, Kofflard, MJM, Boersma, E, Sonke, GS, Levin, M-D & Jager, A 2019, 'Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.', European Journal of Heart Failure, vol. 21, pp. 289-290.

Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors. / Bouwer, N. Nathalie; Steenbruggen, T. G.; Rier, H. N. et al.

In: European Journal of Heart Failure, Vol. 21, 05.2019, p. 289-290.

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

TY - JOUR

T1 - Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.

AU - Bouwer, N. Nathalie

AU - Steenbruggen, T. G.

AU - Rier, H. N.

AU - Kitzen, J. J. E. M.

AU - Beelen, K. J.

AU - Ten Tije, A. J.

AU - De Jong, P. C.

AU - Drooger, J. C.

AU - Holterhues, C.

AU - Van Rosmalen, J.

AU - Kofflard, M. J. M.

AU - Boersma, E.

AU - Sonke, G. S.

AU - Levin, M-D

AU - Jager, A.

PY - 2019/5

Y1 - 2019/5

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000468990703117&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 1388-9842

VL - 21

SP - 289

EP - 290

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

ER -

Incidence of cardiotoxicity over time in patients with HER2-positive metastatic breast cancer on long term treatment with trastuzumab and the potential risk factors.

UN SDGs

Other files and links

Cite this